Effect of inhibition of the ubiquitin-proteasome-system and IκB kinase on airway inflammation and hyperresponsiveness in a murine model of asthma

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 1, 2011, Pages 33-42

  El Hashim, Ahmed Z ^a   Renno, W M ^a   Abduo, H T ^a   Jaffal, S M ^a   Akhtar, S ^a   Benter, I F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Asthma; Inflammation; I B kinase and NF B; Ubiquitin proteasome system

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEXAMETHASONE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHACHOLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OVALBUMIN; PROTEASOME; UBIQUITIN; DEXAMETHASONE SODIUM PHOSPHATE; I KAPPA B KINASE ALPHA; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; I KAPPA B; LEUPEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NITRILE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CELL INFILTRATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EOSINOPHIL; HISTOPATHOLOGY; INFLAMMATORY CELL; LUNG FIBROSIS; LYMPHOCYTE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; CELL COUNT; DOSE RESPONSE; DRUG EFFECT; FIBROSIS; HISTOLOGY; INFLAMMATORY INFILTRATE; LUNG LAVAGE; LYMPHOCYTE MIGRATION; MURINE MODEL; NEUTROPHIL CHEMOTAXIS; OUTCOME ASSESSMENT; OVALBUMIN-INDUCED AIRWAY INFLAMMATION; PROTEIN PHOSPHORYLATION; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BRONCHUS HYPERREACTIVITY; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY;

ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; I-KAPPA B KINASE; I-KAPPA B PROTEINS; LEUPEPTINS; LUNG; MALE; MICE; MICE, INBRED BALB C; NITRILES; OVALBUMIN; PROTEASOME ENDOPEPTIDASE COMPLEX; SULFONES; UBIQUITIN;

EID: 79957863239     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400105     Document Type: Article

References (20)

1. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy 2008; 38:872-97.
2. Sheller JR, Polosukhin VV, Mitchell D, Cheng DS, Peebles RS, Blackwell TS. Nuclear factor kappa B induction in airway epithelium increases lung inflammation in allergen-challenged mice. Exp Lung Res 2009; 35:883-895.
3. Bureau F, Bonizzi G, Kirschvink N, Delhalle S, Desmecht D, Merville MP, Bours V, Lekeux P. Correlation between nuclear factor-kappaB activity in bronchial brushing samples and lung dysfunction in an animal model of asthma. Am J Respir Crit Care Med 2000; 161:1314-21. (Pubitemid 30243847)
4. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, Chung KF. Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med 1998; 158:1585-92.
5. La Grutta S, Gagliardo R, Mirabella F, Pajno GB, Bonsignore G, Bousquet J, Bellia V, Vignola AM. Clinical and biological heterogeneity in children with moderate asthma. Am J Respir Crit Care Med 2003; 167:1490-5. (Pubitemid 37363357)
6. Janssen-Heininger YM, Poynter ME, Aesif SW, et al. Nuclear factor kappaB, airway epithelium, and asthma: avenues for redox control. Proc Am Thorac Soc 2009; 6:249-255.
7. Strnad J, Burke JR. IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges. Trends Pharmacol Sci 2007; 28:142-8. (Pubitemid 46283590)
8. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J. Proteasome inhibition: A novel mechanism to combat asthma. J Allergy Clin Immunol 1999; 104:294-300. (Pubitemid 29420423)
9. El-Hashim A, Yousefi S, Edafiogho I, Raghupathy R, Yousif M, Simon HU. Anti-inflammatory and immunosuppressive effects of the enaminone E121. Eur J Pharmacol 2010; 632:73-78.
10. Han YH, Moon H J, You BR, Park WH. The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep 2009; 1:215-21.
11. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997; 1;272:21096-103. (Pubitemid 27373968)
12. Meiners S, Hocher B, Weller A, et al. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 2004; 44:471-7. (Pubitemid 39281498)
13. Yang G, Abate A, George AG, Weng YH, Dennery PA. Maturational differences in lung NF-kappaB activation and their role in tolerance to hyperoxia. J Clin Invest 2004; 114:669-78. (Pubitemid 39578757)
14. El-Hashim AZ, Wyss D, Zuany-Amorim C. Kinetics of the increased Penh to methacholine and airway eosinophilia in BALB/c mice and their modulation by different dexamethasone treatment regimens. Pulm Pharmacol Ther 2002; 15:467-75. (Pubitemid 35333893)
15. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 2006; 3:255-261.
16. Lupfer C, Patton KM, Pastey MK. Treatment of human respiratory syncytial virus infected BALB/c mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality. Toxicology 2010; 268:25-30.
17. Birrell MA, Wong S, Hardaker EL, Catley MC, McCluskie K, Collins M, Haj-Yahia S, Belvisi MG. IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 2006; 69:1791-800. (Pubitemid 43894295)
18. Ziegelbauer K, Gantner F, Lukacs NW, et al. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 2005; 145:178-92. (Pubitemid 40756522)
19. Sommers CD, Thompson JM, Guzova JA, et al. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J Pharmacol Exp Ther 2009; 330:377-88.
20. Berend N, Salome CM, King GG. Mechanisms of airway responsiveness in asthma. Respirology 2008; 13:624-31.